glp 1 receptor agonists beyond their pancreatic effects GLP-1 as Treatments for Type 2 Diabetes Risk of pancreatic cancer associated

Results Fifty-five studies involving 16,269 participants and 12 GLP-1RAs were included

It enrolled 17,604 adults aged 45 or older with a body mass index (BMI) of 27 kg/m2 or greater and preexisting CVD (prior MI, prior stroke or peripheral artery disease) without diabetes

Its titration schedule is as follows: Week 1 (starting dose) : 0.6 mg per day Week 2: 1.2 mg per day Week 3: 1.8 mg per day Week 4: 2.4 mg per day Week 5 and onwards : 3 mg per day (therapeutic or maintenance dose) Rybelsus (semaglutide) daily oral dosing schedule Rybelsus comes in two formulations: R1 and R2

Figure 4 illustrates the potential pathways of the function of GLP-1RAs against multiple diseases

18 Gastric emptying modulation : Like GLP-1 receptor agonists, allulose delays gastric emptying, contributing to improved postprandial glucose control